Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | BLM | P54132 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4432263 | 1.00 | FFAR3 (0.50) | FFAR3LCKFYNGLRA1SLC6A9 | |
| Acetic Acid SCHEMBL321076 | 0.96 | FFAR3 (0.54) | FFAR3LCKFYNGLRA1SLC6A9 | |
| Acetic Acid SCHEMBL11793424 | 0.96 | FFAR3 (0.54) | FFAR3LCKFYNGLRA1SLC6A9 | |
| Acetic Acid SCHEMBL5363524 | 0.96 | FFAR3 (0.54) | FFAR3LCKFYNGLRA1SLC6A9 | |
| Acetic Acid SCHEMBL6065922 | 0.96 | FFAR3 (0.54) | FFAR3LCKFYNGLRA1SLC6A9 | |
| Acetic Acid SCHEMBL11858011 | 0.96 | FFAR3 (0.54) | FFAR3LCKFYNGLRA1SLC6A9 | |
| Acetic Acid SCHEMBL8942943 | 0.96 | FFAR3 (0.54) | FFAR3LCKFYNGLRA1SLC6A9 | |
| Acetic Acid SCHEMBL243585 | 0.96 | FFAR3 (0.54) | FFAR3LCKFYNGLRA1SLC6A9 | |
| Acetic Acid SCHEMBL2279126 | 0.96 | FFAR3 (0.54) | FFAR3LCKFYNGLRA1SLC6A9 | |
| Acetic Acid SCHEMBL25365455 | 0.93 | FFAR3 (0.50) | FFAR3LCKFYNGLRA1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116359516-A | Kit for detecting total IgE content of serum and application | 郑州安图生物工程股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| US-4883792-A | ANTIFUNGAL CREAM CONTAINING TIPREDANE | E.R. SQUIBB & SONS, INC., A DE CORP. | 1989-11-28 | — | — | US | claimed |
| US-4868170-A | ANTIINFLAMMATORY, OXIDATION RESISTANCE | E. R. SQUIBB & SONS, INC. (US) | 1989-09-19 | — | — | US | claimed |
| US-4868169-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1989-09-19 | — | — | US | claimed |
| EP-0316834-A1 | Steroid cream formulation | E.R. Squibb & Sons, Inc. (US) | 1989-05-24 | — | — | EP | claimed |
| CN-119920630-A | Porous carbon material, preparation method thereof, lithium ion capacitor positive electrode and lithium ion capacitor | 中国石油化工股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-118284808-A | Circulating tumor cell separation kit, circulating tumor cell separation container and circulating tumor cell separation method | 积水医疗株式会社 | 2024-07-02 | — | — | CN | disclosed |
| CN-118235042-A | Blood collection container, method for separating plasma, method for separating extracellular free nucleic acid, and method for separating extracellular vesicle | 积水医疗株式会社 | 2024-06-21 | — | — | CN | disclosed |
| CN-114740120-B | Method for simultaneously and quantitatively determining abiraterone and five metabolites thereof and application | 武汉宏韧生物医药股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117368379-A | Method for high-flux detection of catecholamines and metabolites thereof by liquid chromatography electrochemical method | 北京豪思生物科技股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-116359516-A | Kit for detecting total IgE content of serum and application | 郑州安图生物工程股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-109321561-A | A kind of preservative agent and heparin tube for nucleic acids in blood outside protective | 安诺优达基因科技(北京)有限公司 | 2019-02-12 | — | — | CN | disclosed |
| US-8916614-B2 | Lindane lotion and methods | WOCKHARDT EU OPERATIONS (SWISS) AG (CH) | 2014-12-23 | — | — | US | disclosed |
| US-20090105276-A1 | LINDANE LOTION AND METHODS | WOCKHARDT EU OPERATIONS (SWISS) AG (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-0316834-B1 | STEROID CREAM FORMULATION | E.R. Squibb & Sons, Inc. (US) | 1992-06-24 | — | — | EP | disclosed |
| US-4883792-A | ANTIFUNGAL CREAM CONTAINING TIPREDANE | E.R. SQUIBB & SONS, INC., A DE CORP. | 1989-11-28 | — | — | US | disclosed |
| US-4868170-A | ANTIINFLAMMATORY, OXIDATION RESISTANCE | E. R. SQUIBB & SONS, INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868169-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1989-09-19 | — | — | US | disclosed |
| EP-0316834-A1 | Steroid cream formulation | E.R. Squibb & Sons, Inc. (US) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105276-A1 | LINDANE LOTION AND METHODS | LAGE3, LOXL3, LOXL1 | FFAR3 1067/4885LCK 134/4885FYN 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.